Vistagen reports Q2 net loss $6.6M; fasedienol PALISADE-2 positive; cash $37.6M + $93.5M offering

Vistagen Therapeutics, Inc.

2025-Q2 EPS reported -$1.55 vs consensus -$0.48 ▼ miss (-221.0%)

Net loss $6.6M for Q2 end Sep 30, 2023 vs $17.5M YoY; R&D expense decreased to $3.9M.
Cash $37.6M at Sep 30; raised $93.5M net from public offering plus $1.5M from Fuji Pharma.
Fasedienol PALISADE-2 Phase 3 met primary and secondary endpoints; PALISADE-3 and -4 planned 2024; NDA target 1H 2026.
Itruvone Phase 2B for MDD and PH80 Phase 2B for hot flashes expected 2H 2024; PH80 positive Phase 2A in PMDD.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vistagen Therapeutics, Inc. reported financial results for fiscal year 2024 second quarter ended September 30, 2023.

Period: fiscal year 2024 second quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release to announce the Company’s financial results for its fiscal year 2024 second quarter ended September 30, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-031291

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.